The dermatology and skin care company said Thursday that Stuart Raetzman has been named as global chief executive officer of Galderma Pharma S.A. He reports to Humberto Antunes, chairman of Galderma Pharma S.A. and CEO of Nestle Skin Health S.A. Galderma is the operating company of Nestle Skin Health.
“Galderma’s single focus on dermatology and unique holistic view of skin health distinguish it in the marketplace and position the company to substantially increase its share of the dermatology and aesthetic medicine markets,” Raetzman stated.
Under Raetzman’s leadership, Galderma has recently aligned its North American affiliate structure with the company’s global strategy, transitioning into an organization with three business units: prescription medications, self-medication products, and aesthetic and corrective medical solutions. Galderma’s North American headquarters is in Fort Worth, Texas.
Galderma’s Prescription Business Unit will focus on pharmaceutical products available by prescription. The company currently offers solutions to treat skin diseases such as acne, rosacea, eczema, psoriasis, and melasma, with products including Oracea Capsules, Epiduo Gel, Differin Gel, Mirvaso Gel and, most recently, Soolantra Cream.
The Self-Medication Business Unit includes nonprescription, cosmetic and over-the-counter drug brands. Products include Cetaphil skin cleansers and moisturizers, including Cetaphil Baby, the most recent addition to the line, as well as Galderma’s first over-the-counter acne regimen, Benzac Acne Solutions, was launched in January. The unit is slated to launch more new products this year, according to Galderma.
The Aesthetic and Corrective Business Unit includes products and services for minimally invasive cosmetic treatments.
Also on Thursday, Galderma Laboratories introduced a new leadership team: Todd Zavodnick, appointed president and general manager of Galderma Laboratories; Safia Rizvi, vice president and general manager of the U.S. Prescription Business Unit; and Miles Harrison, vice president and general manager of the U.S. Self-Medication Business. Rizvi joined Galderma from UCB Pharmaceuticals and Harrisonfrom Novartis.
In the interim, Zavodnick will continue leading the Aesthetic and Corrective Business Unit. A new vice president will be appointed in the upcoming months, Galderma said. Philip Brown continues to serve as senior vice president of medical and regulatory affairs.
“Our goal is to grow the number of people the company serves to over a billion within 10 years by offering skin health solutions that primarily maintain, nourish and enhance and if needed, treat, correct and restore the skin to its healthy state,” stated Antunes, newly appointed CEO of Nestle Skin Health. “Solutions that really work for either healthy or compromised skin contribute to the overall health and quality of people’s lives immeasurably, and that’s what we do.”